Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0052 | 0.5849 | 0.6261 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0059 | 0.724 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.007 | 0.9228 | 1 |
Brugia malayi | Bromodomain containing protein | 0.0038 | 0.3378 | 0.2673 |
Schistosoma mansoni | acetyl-CoA C-acetyltransferase | 0.0022 | 0.0535 | 0.0679 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.0052 | 0.5849 | 0.6261 |
Loa Loa (eye worm) | hypothetical protein | 0.0038 | 0.3391 | 0.3541 |
Schistosoma mansoni | bromodomain containing protein | 0.0063 | 0.7886 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.004 | 0.3818 | 0.4014 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0035 | 0.2881 | 0.2123 |
Loa Loa (eye worm) | hypothetical protein | 0.0042 | 0.4163 | 0.4395 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0036 | 0.2951 | 0.4076 |
Echinococcus granulosus | fetal alzheimer antigen falz | 0.0022 | 0.0535 | 0.0739 |
Schistosoma mansoni | hypothetical protein | 0.0021 | 0.0191 | 0.0242 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.0052 | 0.5849 | 0.5407 |
Schistosoma mansoni | hypothetical protein | 0.0035 | 0.2881 | 0.3654 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0036 | 0.2951 | 0.4076 |
Echinococcus multilocularis | fetal alzheimer antigen, falz | 0.0022 | 0.0535 | 0.0739 |
Loa Loa (eye worm) | hypothetical protein | 0.0035 | 0.2881 | 0.2977 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0059 | 0.724 | 1 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0052 | 0.5849 | 0.5407 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (ADMET) | > 100 uM | Antiproliferative activity against immortalized human HS27 cells after 48 hrs by SRB assay | ChEMBL. | 21944286 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.